UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?

Lung cancer (Amsterdam, Netherlands), 2014-04, Vol.84 (1), p.86-91

2014

Volltextzugriff (PDF)

OC-0609: Radiomic CT features for evaluation of EGFR and KRAS mutation status in patients with advanced NSCLC

Radiotherapy and oncology, 2016-04, Vol.119, p.S290-S291

2016

Volltextzugriff (PDF)

Prospective Validation of a Prognostic Computed Tomography–Based Radiomic Signature in Stage IV Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S192-S192

2016

Volltextzugriff (PDF)

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Current problems in cancer. Case reports, 2022-09, Vol.7, p.100186, Article 100186

2022

Volltextzugriff (PDF)

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches

Annals of oncology, 2022-09, Vol.33 (9), p.893-908

2022

Volltextzugriff (PDF)

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

Annals of oncology, 2022-02, Vol.33 (2), p.123-125

2022

Volltextzugriff (PDF)

106P Generation of synthetic ground glass opacities (GGOs) using generative adversarial networks (GANs)

Annals of oncology, 2022-04, Vol.33, p.S80

2022

Volltextzugriff (PDF)

77P Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study

Annals of oncology, 2021-09, Vol.32, p.S389-S389

2021

Volltextzugriff (PDF)

EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S349

2022

Volltextzugriff (PDF)

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

Lung cancer (Amsterdam, Netherlands), 2021-05, Vol.155, p.163-169

2021

Volltextzugriff (PDF)

Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population

European journal of cancer (1990), 2023-09, Vol.190, p.112947-112947, Article 112947

2023

Volltextzugriff (PDF)

Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis

Patient education and counseling, 2023-04, Vol.109, p.12

2023

Volltextzugriff (PDF)

O.5.2 - Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis: Presenter(s): Inge Henselmans, Amsterdam University Medical Centers, Netherlands

Patient education and counseling, 2023-04, Vol.109

2023

Volltextzugriff (PDF)

OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S26-S27

2024

Volltextzugriff (PDF)

1283P Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features

Annals of oncology, 2021-09, Vol.32, p.S997-S997

2021

Volltextzugriff (PDF)

Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation

Respiratory medicine case reports, 2012-01, Vol.5, p.37-39

2012

Volltextzugriff (PDF)

OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S55-S56

2023

Volltextzugriff (PDF)

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-07, Vol.121, p.76-81

2018

Volltextzugriff (PDF)

1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

Annals of oncology, 2021-09, Vol.32, p.S966-S966

2021

Volltextzugriff (PDF)

LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Annals of oncology, 2021-09, Vol.32, p.S1327-S1327

2021

Volltextzugriff (PDF)

EP-1380: Can radiomic features describe lung semantic features in NSCLC patients?

Radiotherapy and oncology, 2018-04, Vol.127, p.S753-S754

2018

Volltextzugriff (PDF)

PO-0779 Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey

Radiotherapy and oncology, 2019-04, Vol.133, p.S402-S403

2019

Volltextzugriff (PDF)

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study

Lung cancer (Amsterdam, Netherlands), 2024-05, Vol.191, p.107792, Article 107792

2024

Volltextzugriff (PDF)

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

Respiratory medicine and research, 2020-11, Vol.78, p.100788

2020

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Kollektion

EZB Free E-Journals
(13)
IngentaConnect
(13)
Elsevier ScienceDirect Journals Complete
(13)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(11)
Journals@Ovid Full Text
(10)
MEDLINE
(6)
IngentaConnect Journals
(2)

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?

OC-0609: Radiomic CT features for evaluation of EGFR and KRAS mutation status in patients with advanced NSCLC

Prospective Validation of a Prognostic Computed Tomography–Based Radiomic Signature in Stage IV Non-Small Cell Lung Cancer

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches

Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease

106P Generation of synthetic ground glass opacities (GGOs) using generative adversarial networks (GANs)

77P Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study

EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population

Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis

O.5.2 - Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis: Presenter(s): Inge Henselmans, Amsterdam University Medical Centers, Netherlands

OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01

1283P Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features

Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation

OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer

1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

EP-1380: Can radiomic features describe lung semantic features in NSCLC patients?

PO-0779 Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

Suchergebnisse filtern